Sugi Predict

Sugi Predict / Compounds / SCHEMBL1361023

SCHEMBL1361023

SCHEMBL1361023

COCCOCOc1cc2ccc(-c3ccc(C(=O)O)cc3)cc2cc1C12CC3CC(CC(C3)C1)C2

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ IKBKB O14920 5/20 0.63
▸ RARA P10276 7/20 0.62
▸ MEN1 O00255 3/20 0.59
▸ KMT2A Q03164 3/20 0.59
▸ THRB P10828 1/20 0.59
▸ RECQL P46063 1/20 0.59
▸ NR2E1 Q9Y466 1/20 0.59
▸ RARG P13631 10/20 0.59
▸ RARB P10826 8/20 0.59
▸ NR1I2 O75469 1/20 0.59
▸ LMNA P02545 1/20 0.59
▸ PGR P06401 1/20 0.59
▸ HSPD1 P10809 1/20 0.59
▸ GOT1 P17174 1/20 0.59
▸ GLRA1 P23415 1/20 0.59
▸ BLM P54132 1/20 0.59
▸ HSPE1 P61604 1/20 0.59
▸ TDP1 Q9NUW8 1/20 0.59
▸ KDM4E B2RXH2 1/20 0.50
▸ ALDH1A1 P00352 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7927677 0.92 IKBKB (0.53) IKBKBRARAMEN1KMT2ATHRB
SCHEMBL7929428 0.92 IKBKB (0.53) IKBKBRARAMEN1KMT2ATHRB
SCHEMBL6032190 0.90 IKBKB (0.62) IKBKBRARAMEN1KMT2ATHRB
SCHEMBL7517470 0.90 RARB (0.65) IKBKBRARAMEN1KMT2ATHRB
SCHEMBL19755562 0.89 IKBKB (0.49) IKBKBRARAMEN1KMT2ATHRB
SCHEMBL7930000 0.89 IKBKB (0.51) IKBKBRARAMEN1KMT2ATHRB
SCHEMBL7926536 0.89 IKBKB (0.50) IKBKBRARAMEN1KMT2ATHRB
SCHEMBL7929849 0.89 RARB (0.64) IKBKBRARAMEN1KMT2ATHRB
SCHEMBL7929470 0.89 IKBKB (0.51) IKBKBRARAMEN1KMT2ATHRB
SCHEMBL7926669 0.89 IKBKB (0.49) IKBKBRARAMEN1KMT2ATHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 143 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026086823-A1 IN VITRO PRODUCTION OF EXPANDED POTENTIAL STEM CELLS Centre for Translational Stem Cell Biology Limited (CN) 2026-04-30 — — WO claimed
US-20250345316-A1 METHODS OF INCREASING LYMPHOCYTE TRAFFICKING TO THE COLON BY STIMULATING RETINOIC ACID RECEPTORS AND ARYL HYDROCARBON RECEPTORS PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2025-11-13 — — US claimed
US-20240018227-A1 COMPOSITIONS AND METHODS FOR TREATING DISORDERS CHARACTERIZED WITH TGF-BETA ACTIVITY THE JOHNS HOPKINS UNIVERSITY 2024-01-18 — — US claimed
WO-2022093967-A1 COMPOSITIONS AND METHODS FOR TREATING DISORDERS CHARACTERIZED WITH TGF-BETA ACTIVITY THE JOHNS HOPKINS UNIVERSITY (US) 2022-05-05 — — WO claimed
US-8066976-B2 Foaming compositions for hair care GALDERMA S.A. (CH) 2011-11-29 — — US claimed
US-20100234337-A1 FOAMING COMPOSITIONS FOR HAIR CARE GALDERMA S.A. (CH) 2010-09-16 — — US claimed
US-20100144683-A1 METHODS FOR GENERATING MAMMALIAN MODELS OF ATOPIC DISEASES, AND SCREENING FOR THEIR TREATMENT ASSOCIATION POUR LA RECHERCHE A L'IGBMC (ARI) (FR) 2010-06-10 — — US claimed
EP-2046309-A2 USE OF VITAMIN D3 AGONIST IN A MAMMALIAN MODEL FOR ATOPIC DISEASES AND OF VITAMIN D3 ANTAGONISTS FOR THE TREATMENT OF ATOPIC DISEASES Association pour la recherche à l'IGBMC (ARI) (FR) 2009-04-15 — — EP claimed
EP-1891944-A1 Use of Vitamin D3 agonist in a mammalian model for atopic diseases and of Vitamin D3 antagonists for the treatment of atopic diseases Association pour la recherche à l'IGBMC (ARI) (FR) 2008-02-27 — — EP claimed
WO-2008012645-A2 USE OF VITAMIN D3 AGONIST IN A MAMMALIAN MODEL FOR ATOPIC DISEASES AND OF VITAMIN D3 ANTAGONISTS FOR THE TREATMENT OF ATOPIC DISEASES ASSOCIATION POUR LA RECHERCHE A L'IGBMC (ARI) (FR) 2008-01-31 — — WO claimed
EP-1087747-B1 FOAMING COMPOSITION FOR HAIR CARE GALDERMA SA (CH) 2005-11-09 — — EP claimed
EP-0874626-B1 USE OF INHIBITORS OF RETINOIC ACID ACTIVITY FOR WOUND HEALING CT INTERNAT DERECH S DERMATOLO (FR) 2004-12-29 — — EP claimed
EP-0892633-B1 USE OF INHIBITORS OF THE ACTIVITY OF RETINOIC ACID FOR TREATING SENSITIVE SKIN AND/OR ACUTE DAMAGE INDUCED BY UV RADIATION GALDERMA RECH DERMATOLOGIQUE (FR) 2003-03-05 — — EP claimed
EP-0854711-B1 gamma-RAR ANTAGONIST LIGAND OR alpha-RAR AGONIST LIGAND AS AN APOPTOSIS INHIBITOR GALDERMA RECH DERMATOLOGIQUE (FR) 2002-01-23 — — EP claimed
US-6248749-B1 TOPICALLY APPLYING RETINOID ANTAGONIST TO SENSITIVE SKIN TO TREAT ALLERGIES/SUNBURN CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) 2001-06-19 — — US claimed
US-6063797-A γ-RAR antagonist ligand or α-RAR agonist ligand as an apoptosis inhibitor C.I.R.D. GALDERMA (FR) 2000-05-16 — — US claimed
US-5973007-A SURGERY, TRAUMA WOUNDS CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) 1999-10-26 — — US claimed
EP-0658553-B1 Polycyclic aromatic compounds, pharmaceutical and cosmetic compositions containing them and uses thereof CIRD GALDERMA (FR) 1998-11-04 — — EP claimed
WO-2026098697-A1 NOVEL ANTIBACTERIAL USE OF RETINOID COMPOUND 首都儿科研究所 2026-05-15 — — WO disclosed
US-5973007-A SURGERY, TRAUMA WOUNDS CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) 1999-10-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100234337-A1 FOAMING COMPOSITIONS FOR HAIR CARE RARA, NR5A1, SHH IKBKB 3920/4885RARA 1/4885MEN1 2113/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.